Eli Lilly Cuts Zepbound Price to Widen Access for Obesity Drug

Date:

The Eli Lilly logo on one of the company’s offices in San Diego, Calif., on Sept. 17, 2020. Mike Blake/ReutersEli Lilly said on Monday it has lowered the price of single-dose vials of its popular obesity drug Zepbound to make the treatment more affordable for U.S. patients, as demand for weight-loss therapies surge.Patients with a prescription can now buy the starting dose of 2.5 mg for $299 per month, down from $349, through LillyDirect, the drugmaker’s online healthcare platform.

spot_imgspot_imgspot_img

Share post:

More like this
Related

Real Investment Coming, Trade Adviser Says as US Manufacturing Grows for 5th Straight Month

Trump is prioritizing heavy industries such as aerospace, automotive,...

BlackRock, Fidelity May Be Replaced as Managers of New York City Pension Funds

The midtown Manhattan skyline is pictured from the top...

Indiana Tops Housing Affordability Report Card While New York Ranks Last: Realtor

A home for sale in a Brooklyn neighborhood in...

Bank of Japan Raises Interest Rates to Highest Level Since 1995

A passerby walks past the Bank of Japan headquarters...